eToro: Buy Shares with 0% Commission

Your capital is at risk

How to Buy AstraZeneca Shares UK – With 0% Commission

AstraZeneca is known widely as one of the world’s largest pharmaceutical companies and the maker of a COVID-19 vaccine. However, the drug developer has also run into trouble in recent months with rolling out its vaccine. So is now a good time to buy or sell AstraZeneca shares?

In this guide, we’ll show you how to buy AstraZeneca shares online in the UK and take a look at why now might be the best time to buy AZN shares.

Step 1: Find a UK Stock Broker That Offers AstraZeneca Shares

AstraZeneca Logo The easiest way to buy or sell AstraZeneca shares in the UK is to use a registered online stock broker. With a stock broker, you can buy shares of not just AstraZeneca, but also other popular stocks like Amazon, Netflix, easyJet, and more.

Choosing the right UK share broker is critical since this will impact everything from what companies you can trade to how much it costs. To help you find the right one, let’s take a closer look at two of our most highly recommended UK brokers.

1. eToro – Buy AstraZeneca Shares with No Commission

eToro is one of the top stock brokers in the UK, with trading on more than 800 shares from around the globe. You can buy stocks on the London, New York, and Tokyo Stock Exchanges, among others, for access to many of the best shares from anywhere in the world.

You can choose to buy shares in the traditional sense, or you can trade shares through contracts for difference (CFDs), allowing you to go shirt and can increase your effective positions using leverage up to 5:1.

One of the things we like most about eToro is that all trading is 100% commission-free. You don’t pay a pence in fees when you buy and sell shares. Rather, you just cover the spread, which is usually well below the industry average. eToro does have some account fees to keep track of, but most of them are easy to avoid.

eToro also has a built-in social trading network, which you can use to generate new trade ideas. The platform enables you to strike up a discussion with other investors. You can also use the copy trading feature to automatically mimic the positions of a more experienced trader.

eToro is fully regulated and subject to the authority of the UK’s Financial Conduct Authority. In addition, you can feel confident in this broker because all accounts are secured by the government’s Financial Services Compensation Scheme. The platform also lists an excellent investment app, in addition to a wide range of payment methods that include PayPal.


  • More than 800 shares
  • Buy shares or trade CFDs
  • 100% commission-free trading
  • Leverage up to 5:1
  • Low share trading spreads
  • Fully regulated by the FCA
  • Social trading network with copy trading


  • Some account fees

67% of retail investor accounts lose money when trading CFDs with this provider.

2. Plus500 – Share CFD Trading with Tight Spreads

Plus500 LogoIf you’re looking to maximize your position in AstraZeneca or another UK share, Plus500 may be the best broker for you. This CFD broker enables you to trade shares with leverage up to 1:5. So, you can take a large stake in a company with relatively little money in your account. You’ll find shares for around 500 companies available through this broker, most of them based in the UK or US.

Plus500, like eToro, is 100% commission-free for share CFD trading. The broker’s spreads are very low and there are few account fees. In our view, this is one of the most cost-effective stock brokers in the UK right now.

This brokerage comes with a feature-packed trading platform that includes price alerts, an economic calendar, and built-in charting. The technical charts are aimed more at beginner investors. You get access to nearly 100 different technical studies, but you won’t get access to the customization features that more experienced traders demand. For trading on the go, Plus500 also offers a handy mobile stock trading app.

Plus500 is fully regulated by the UK’s Financial Conduct Authority along with regulators from other European nations. In addition, all accounts are backed by the Financial Services Compensation Scheme, so you can be sure your funds are safe.


  • Trade nearly 500 shares through CFDs
  • 100% commission-free trading
  • Leverage up to 1:5 for share trades
  • Built-in technical charts
  • Price alert feature
  • Regulated by the FCA


  • Charting features are limited

72% of retail investors lose money trading CFDs at this site

Step 2: Research AstraZeneca Shares

AstraZeneca is a household name, but that doesn’t necessarily mean that it’s worth investing in or that now is the right time to buy. In order to determine whether you should add AZN shares to your portfolio, it’s important to do some background research about this drug maker and the AstraZeneca share price. We’ll cover all the basics you need to know in order to decide if AstraZeneca shares are worthwhile for you.

AstraZeneca Share Price History

AstraZeneca is a gigantic corporation with a market capitalization of more than £110 billion. But this pharmaceutical company is also a relatively new one – it was formed in 1999. Before that, Astra was a Swiss drug manufacturer. Zeneca was the pharmaceutical division of UK agrochemical manufacturer ICI, but it was broken off from its parent company in 1993. Astra and Zeneca merged in 1999 to become one of the largest pharmaceutical companies in the world at the time.

AstraZeneca has grown enormously since the merger. It has acquired a number of medium-sized drug companies, including UK firms like Cambridge Antibody Technology. In addition, AstraZeneca has poured money into research and development to create treatments for cancer, cardiovascular disease, infections, respiratory illnesses, and gastrointestinal problems.

The AstraZeneca share price has reflected its growth over the past two decades. When AstraZeneca first listed on the London Stock Exchange, shares sold for around 2,500 pence. Today, AstraZeneca shares are priced at over 7,0000 pence. Much of that growth has come in the past several years after the company announced a restructuring in 2013 and rejected a takeover bid from Pfizer in 2014.Astrazeneca Stock Chart

AstraZeneca’s share price reached new all-time highs in the summer of 2020 thanks to the coronavirus pandemic. The company announced in late April that it partnered with Oxford University to develop a vaccine candidate. By July, AstraZeneca was moving its vaccine candidate into a combined Phase 2/3 trial, and the company’s vaccine received approval from the EU in January 2021.

However, the rollout has been anything but smooth. The EU initially paused the Astrazeneca vaccine distribution because of fears over blood clots, but restarted the rollout in March after finding no link between the vaccine and clots. At the same time, the EU has been publicly fighting with Astrazeneca over the number of doses being manufactured. Limited supply of the Astrazeneca vaccine and shipments out of the EU to other countries have badly hurt the company’s image.

As a result, the share price currently sites at just over 7,700 pence – down from an all-time high of 10,120 pence last year.

AstraZeneca Shares Dividend Information

AstraZeneca has long been a favourite stock for UK dividend investors. This blue chip stock pays out a handsome dividend of 218 pence, which equates to a yield of around 2.8%.

That yield won’t top the list of UK dividend shares, but it’s nothing to sniff at considering the AstraZeneca share price appreciation. Notably, the AstraZeneca shares dividend has been pushed ahead with even as many other companies in the UK and around the world have cut back on their payments to shareholders during the coronavirus pandemic.

Should I Buy AstraZeneca?

Analysts are excited about AstraZeneca, and they have good reason to be. Despite the fact that Astrazeneca’s public image has suffered in recent months, this company has shown extremely strong performance and is still one of just a few companies with an approved COVID-19 vaccine. So, should you buy AstraZeneca shares right now?

COVID-19 Vaccine

The main thing that’s impacting the AstraZeneca share price right now is the production and rollout of the COVID-19 vaccine. This hasn’t gone well for the company. Although the vaccine is approved in the EU, it’s widely mistrusted after the halt related to blood clot fears. The vaccine isn’t approved in the US, even though the country has stockpiled millions of doses.

This has hurt the share price – AstraZeneca shares are down nearly 25% from their high last fall. However, there’s reason to be optimistic.

AstraZeneca may face an uphill battle in the EU, but the demand for its COVID-19 vaccine is global. From the beginning, AstraZeneca sought to provide its vaccine at a cost that was accessible to developing nations. So as it ramps up production, its vaccine could become the leading shot in countries in Africa, South America, and South Asia.

In the long run, AstraZeneca has also gotten a taste of how vaccine development and manufacturing works. So it could be a leading contender the next time the world needs a new vaccine.

Cancer Treatments are Taking Off

AstraZeneca drug packagingAstraZeneca has received a lot of attention lately for its coronavirus vaccine candidate, but the company’s true strength lies in oncology. AstraZeneca’s cancer treatments account for 40% of the company’s revenue as of 2019.

Even better, sales of the company’s blockbuster cancer treatments are on the rise. Tagrisso, a drug for treating lung cancer, brought in more than £770 million last year – a year-over-year revenue increase of 58% for that treatment alone.

Expect to see AstraZeneca continue to dominate this market. As it does, the company will continue squeezing even better margins from its cancer treatments and provide a big boost to its bottom line.

Dividend Growth is Likely

That growing bottom line, in turn, means that AstraZeneca is likely to provide even greater rewards for shareholders in the future. The company’s 2.8% dividend yield is below average for the FTSE 100, and in fact the yield has been falling as the AstraZeneca share price appreciation has outpaced dividend growth.

While nothing is certain, it’s likely that AstraZeneca is aware of this trend and may look to remedy it in the future. That could mean a one-time special dividend, particularly if the coronavirus vaccine is successful. Or it could be that the company will slowly ratchet up its dividend payouts in order to better reward shareholders.

Many Drugs in the Pipeline

AstraZeneca has poured money into research and development in recent years, and the fruits of that effort are likely to be borne in the next few years. The company currently has 167 projects in different stages of completion. Even if only a few of those drugs end up making it to market, that potentially represents billions in sales each year going forward.

Step 3: Open an Account and Deposit Funds

Now that you’ve done your research on AZN shares, the next step is to open a brokerage account. We’ll walk you through the process using our recommended broker eToro, which offers a quick sign up process, commission-free trading, and access to shares on the London Stock Exchange.

To get started, navigate to the broker’s website and choose ‘Join Now’ on the homepage. You’ll be prompted to pick a username and password for your account. You’ll also need to provide a few personal details, including your name, address, birthdate, and contact information.eToro sign up

67% of retail investor accounts lose money when trading CFDs with this provider.

To comply with government regulations, eToro requires that you verify your identity. You will need to upload a copy of your driver’s license or passport along with a utility bill or bank account statement that shows your address. Verification happens automatically online once your documents are uploaded.

eToro requires a minimum deposit of £160 to start trading with your new account. You can make a deposit using a variety of different methods, including:

  • Debit card
  • Credit card
  • PayPal
  • Skrill
  • Neteller
  • Bank transfer
  • Wire transfer (extra charge applies)

If you fund your account with a debit card, credit card or e-wallet, your funds will be available for trading instantly.

Step 4: Buy AstraZeneca Shares

Once your account is funded, you’re ready to buy AstraZeneca shares. From your account dashboard, enter ‘AstraZeneca’ into the search box at the top of the page. When the company appears in the drop-down menu, click on it. Search AstraZeneca on eToro

On the AstraZeneca shares page that appears, click ‘Trade’ to open an order form.Trade AstraZeneca shares on eToro

67% of retail investor accounts lose money when trading CFDs with this provider.

The form now in front of you is used to submit your order for AstraZeneca shares to eToro. You can buy or sell AstraZeneca shares in any amount as long as your transaction involves a minimum of £40. If you want to set a stop loss or take profit level for your trade, you can also do that using the order form. You also get to choose whether or not you want to apply leverage to your trade.Buy AstraZenece shares on eToro

When your order form is ready, click ‘Open Trade’ to buy AstraZeneca shares.

AstraZeneca Shares Buy or Sell

Investors have recently wavered on AstraZeneca shares because of the company’s difficulties in rolling out its COVID-19 vaccine. However, we believe that AstraZeneca has a number of tailwinds behind it that bode well for the company.

First, the COVID-19 asset is currently a weakness, but it’s also a potential source of strength for AstraZeneca. The company is ramping up manufacturing and it has been proven safe even after additional scrutiny from EU regulators. Over the next year, expect to see AstraZeneca shots being delivered in enormous quantities to developing countries around the world.

Another source of strength is AstraZeneca’s oncology division, which accounts for a much larger portion of revenue than than the COVID-19 vaccine. AstraZeneca is already a leader in cancer-fighting drugs, and its position in this market is growing bigger year after year. This alone should be enough to continue pushing the share price higher in years to come.

All in all, AstraZeneca shares look like a bargain right now. The share price is down 25% from its all-time high. We think AstraZeneca shares are a strong buy and have a lot of potential upside for long-term investors.

The Verdict

AstraZeneca shares have been the darling of traders, investors, and analysts alike in recent years. This pharmaceutical giant has seen massive share price appreciation in recent years while offering an attractive dividend yield of 2.8%.

AstraZeneca has been in the news most recently for its COVID-19 vaccine and the poor rollout in Europe has driven the share price lower. But the company’s bread and butter lies in cancer treatments and other high-revenue drugs. With more than 160 candidate drugs in various stages of development, AstraZeneca’s strength shows no signs of waning.

Ready to buy AstraZenece shares? Invest in stocks today by signing up for an account with eToro – just click the link below to get started.

eToro – Buy AstraZeneca Shares With No Commission

67% of retail investor accounts lose money when trading CFDs with this provider.

Other Vaccine Shares

Interested in investing in other pharmaceutical companies that are involved in developing a coronavirus vaccine? Check out the list below.


Is AstraZeneca only traded on the London Stock Exchange?

Can I collect dividends when trading CFDs?

Does AstraZeneca operate in global markets?

How much does AstraZeneca spend on research?

Will AstraZeneca’s dividend grow over time?

About Michael Graw PRO INVESTOR

Michael Graw is a freelance journalist based in Bellingham, Washington. He covers finance, trading, and technology. His work has been published on numerous high-profile websites that cover the intersection of markets, global news, and emerging tech. In addition to covering financial markets, Michael’s work focuses on science, the environment, and global change. He holds a Ph.D. in Oceanography from Oregon State University and worked with environmental non-profits across the US to bridge the gap between scientific research and coastal communities. Michael’s science journalism has been featured in high-profile online publications such as Salon and Pacific Standardas well as numerous print magazines over the course of his six-year career as a writer. He has also won accolades as a photographer and videographer for his work covering communities on both coasts of the US. Other publications Michael has written for include TechRadar, Tom’s Guide, StockApps, and LearnBonds.

Read next